Alex De Caluwe

Neo-CheckRay phase 2 trial results #SABCS25 A novel immuno-modulating strategy 💡#radonc #medonc #BreastCancer @OncoAlert #OncoAlert

📌 What to de-escalate and for which breast patients? De-escalation in breast surgery, radiation and systemic treatment 🔸 Comprehensive radiation therapy: For whom and when @AlexDeCaluwe 👏🏻 #ESMO25 @OncoAlert #OncoAlertAF

🔬 The Neo-CheckRay trial explored pre-op immune-modulating SBRT (8 Gy x 3) + immunotherapy in luminal B breast cancer, sparing tumor-draining lymph nodes to avoid immunosuppression. Feasible, but more research needed! thegreenjournal.com/article/S0167-… #BreastCancer #RadiationOncology

Investigator-initiated study sponsored by @JulesBordet and chaired by @AlexDeCaluwe and Laurence Buisseret. Primary endpoint results presented at #ESMO24 oncologypro.esmo.org/meeting-resour…

October is #BreastCancerAwarenessMonth 📣 Check out this interview from #ESMO2024 w/ @AlexDeCaluwe | Neo-CheckRay: #chemotherapy and SBRT with #durvalumab and #oleclumab in #ER+/#HER2- #breastcancer 🎥 👉 vjoncology.com/video/3trnjmui…

👏Fascinating results on RT + IO in breast cancer presented by my good friend @AlexDeCaluwe at this year's #ESMO2024 - makes you dream about a similar concept in #GIonc 🤔

@oncomarvelmd @VJOncology Hi Arthur, the results have been presented at the last ESMO. Here is a summary: dailyreporter.esmo.org/esmo-congress-…

@Mat_Guc @Icro_Meattini Breast cosmesis is an endpoint in this trial and will be reported later.

@Mat_Guc @Icro_Meattini Thank you for highlighting our work! For radoncs: we are finalising a manuscript detailing dose prescription and constraints. We were very strict for skin / chest wall constraints because these patients receive adjuvant RT as well. PTV and GTV were sometimes underdosed.

Randomized phase 2 trial evaluating SBRT to the Primary Breast Cancer +/- Durvalumab +/- Oleclumab combined with Neoadjuvant Chemotherapy for Early-Stage High Risk ER+/HER2- 👉 high rates of pCR especially in PD-L1 neg pts

At #ESMO24 @AlexDeCaluwe presents results of NeoCheckRay, evaluating SBRT⚡️+/- durva +/- oleclumab combined with NACT in Luminal B EBC Promising activity of RT-IO combination in ⬆️pCR/RCB 0-1 in these cold tumors, especially in the subgroup with PD-L1 tumors 🥶➡️🥵 @OncoAlert

NEOCheck-Ray: does adding #durvalumab and SBRT to neoadjuvant chemotherapy improves pCR in Lum B #ebc ? @AlexDeCaluwe @JulesBordet @OncoAlert  #ESMO24 #ESMOAmbassadors

#ESMO24 proffered eBC session Neo-CheckRay trial presented by @AlexDeCaluwe demonstrated numerically ⬆️ RCB0/1 with Durvalumab + Oleclumab + SBRT during neoadjuvant tp in high-risk, HR+ eBC. 🔎 Impressive responses with ICIs + SBRT in PDL1 neg disease! @OncoAlert @JulesBordet

Very interesting results by PD-L1 status Unlike Keynote756 and Checkmate7FL, which showed higher benefit of IO in PD-L1+, Neo-CheckRay found greater benefit in PD-L1- pts, suggesting SBRT may be a particularly effective IO priming strategy for this population @OncoAlert

Neo-CheckRay presented by @AlexDeCaluwe Ph2 II trial in early LumB BC, exploring NACT + SBRT + IO (anti-PD-L1, anti-CD73) The addition of IO to NACT+SBRT numerically improved RCB0/1 rates (38% vs 51%, P = 0.2) Incredibly proud to be part of this effort! @OncoAlert

Congratulations @AlexDeCaluwe and Bordet team for this timely study focus on crucial topic RT-drug synergy Primary endpoint results NEO-CHECKRAY phase 2 trial #ESMO24 @OncoAlert #OncoAlert #radonc #medonc

⏳Can’t wait for the eBC proffered session about to start at 10:15 in #ESMO24 Barcelona Auditorium! @AlexDeCaluwe from @JulesBordet will be presenting primary results of Neo-CheckRay trial. ➡️ Intriguing results on SBRT + Immunotherapy in neoadjuvant HR+ eBC! @OncoAlert

The beautiful @JulesBordet family is reunited in Barcelona for the European Society of Medical Oncology annual meeting 2024 #ESMO24! We come back with the updates in oncology and lots of new projects to help our patients 💥🎗

The trial for small cell lung cancer Adriatic Durvalumab consolidation post CTRT for Limited stage SCLC. HR PFS -16.6 vs 9.2 months - HR 0.76 OS- 55. 9 vs 33.4 HR- 0.73 Toxicity - Same in both arms -24.3 vs 24.2 % - pneumonits 38 % vs 30 % Cross over - we need to check out Impressive results 👏 @asco @JackWestMD @DrRiyazShah @Alfdoc2 @brunolarvol @5_utr @Larvol

Where is RT 👀? Despite overall dearth of RCTs comparing local modalities in HCC, we have randomized studies in support of RT across the disease spectrum: Early/Intermediate stage: Loma Linda trial - RT (protons) vs. TACE: similar OS, RT better PFS & local control Unresectable/Recurrent: RTOG 1112 (sorafenib +/- SBRT): SBRT better OS Palliative: CCTG HE.1 (BSC vs. single fraction RT): RT improved pain Sorry to miss the discussion @OncBrothers - hope there is a next time!